SRPT Sarepta Therapeutics, Inc.

SRPT Sarepta Therapeutics, Inc.

Healthcare · Biotechnology

Market read

Scan convergence 2 scans as of 2026-08-17 1 bear 1 neutral converging

POC $18.01 · VWAP $19.39 · -6.3% vs 12m avg buyer

downtrend vol: compressedchurn: quiet as of

Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)

Coverage

2 watchlists

Watchlists @biotech-scan@ibb

SRPT Price Structure

Loading chart…

Loading timeframes…

Peers

Every watchlist SRPT belongs to, members best 30-day change first — SRPT highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.

@ibb
View watchlist →
ABCL+73.1% -1.6%1d +19.9%7d TXG+32.6% +3.4%1d -1.1%7d TWST+32.6% +4.9%1d -0.3%7d REGN+19.1% +0.3%1d -0.3%7d NTRA+15.8% +1.4%1d -1.4%7d ARGX+14.8% +16.0%1d +14.1%7d AMGN+14.5% +1.0%1d +0.5%7d RVMD+13.9% +4.1%1d +2.5%7d CRSP+13.6% +1.4%1d +1.6%7d SDGR+13.6% -1.1%1d -7.4%7d PTGX+12.6% +2.3%1d +5.9%7d BMRN+11.8% -1.1%1d -3.3%7d ABSI+11.3% +0.7%1d +2.5%7d MEDP+11.0% +3.2%1d -0.9%7d IONS+7.8% +2.4%1d +3.0%7d NKTR+6.5% -0.5%1d -2.9%7d NTLA+6.2% +1.5%1d +0.6%7d VRTX+6.2% +1.9%1d -1.6%7d SRPT+5.6% +0.4%1d +5.9%7d INCY+5.3% +2.8%1d +1.6%7d KYMR+4.9% +3.4%1d +11.8%7d MRNA+4.3% +1.8%1d +7.7%7d ILMN+3.5% +1.2%1d +0.7%7d GILD+3.5% +0.4%1d +4.4%7d IBRX+3.1% +4.6%1d +5.7%7d BIIB+1.5% -0.3%1d +1.0%7d BNTX+0.1% -1.6%1d -1.3%7d ICLR-0.3% +3.9%1d +2.0%7d BEAM-1.6% +1.3%1d -0.6%7d TEM-1.6% -0.9%1d -6.2%7d COGT-3.1% -0.2%1d -8.7%7d EDIT-4.7% +0.7%1d +0.7%7d LEGN-7.2% +1.4%1d -0.1%7d RARE-10.8% -1.4%1d -2.6%7d PACB-16.0% +5.2%1d +4.3%7d ALNY-16.0% -1.8%1d +3.5%7d QTRX-24.6% +12.7%1d +21.2%7d
@biotech-scan
View watchlist →
REGN+19.1% +0.3%1d -0.3%7d IQV+17.0% +1.9%1d -0.2%7d DXCM+15.8% -1.1%1d +1.3%7d AMGN+14.5% +1.0%1d +0.5%7d CRSP+13.6% +1.4%1d +1.6%7d ISRG+13.0% -1.1%1d -0.8%7d A+12.9% -0.1%1d -0.2%7d PTGX+12.6% +2.3%1d +5.9%7d BMRN+11.8% -1.1%1d -3.3%7d TMO+10.0% -0.5%1d -2.3%7d MDT+8.9% -0.7%1d +1.3%7d IMVT+8.6% +4.5%1d +9.8%7d LABU+8.2% +3.9%1d +2.5%7d IONS+7.8% +2.4%1d +3.0%7d NKTR+6.5% -0.5%1d -2.9%7d IBB+6.4% +1.9%1d +0.9%7d NTLA+6.2% +1.5%1d +0.6%7d VRTX+6.2% +1.9%1d -1.6%7d RXRX+5.8% -1.6%1d -5.2%7d SRPT+5.6% +0.4%1d +5.9%7d INCY+5.3% +2.8%1d +1.6%7d IBBQ+5.2% +1.4%1d +0.5%7d KYMR+4.9% +3.4%1d +11.8%7d MRNA+4.3% +1.8%1d +7.7%7d ILMN+3.5% +1.2%1d +0.7%7d GILD+3.5% +0.4%1d +4.4%7d XBI+3.4% +1.4%1d +1.0%7d BIIB+1.5% -0.3%1d +1.0%7d LLY+0.3% +0.3%1d -3.8%7d BNTX+0.1% -1.6%1d -1.3%7d DHR-0.6% +0.1%1d -3.2%7d BEAM-1.6% +1.3%1d -0.6%7d ABBV-1.6% +0.3%1d +1.0%7d COGT-3.1% -0.2%1d -8.7%7d EDIT-4.7% +0.7%1d +0.7%7d LEGN-7.2% +1.4%1d -0.1%7d RARE-10.8% -1.4%1d -2.6%7d NVO-10.8% -2.2%1d -6.0%7d DNA-12.5% +1.9%1d -9.4%7d ALNY-16.0% -1.8%1d +3.5%7d

Next earnings SRPT reports in 78 days Nov 4

Last report May 6

Reported the quarter ending 2026-03-31: revenue $331M, diluted EPS $2.88, net income $331M (SEC filing). Across the print the stock moved -4.5% (close before → first close after).

full note →

Against street estimates

How SRPT's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.

8 most recent of 10 quarters · newest report Aug 5 · projection Aug 17

Result
Aug 5 0.490.64+31.7%Beat
May 6 1.053.16+202.1%Beat
Feb 25 -0.77-3.58-365.3%Miss
Nov 3 '25 -0.37-0.13 GAAP ≠ +65.0%Beat
Aug 6 '25 1.162.02+73.9%Beat
May 6 '25 -0.65-3.42-426.6%Miss
Feb 26 '25 2.061.90-7.8%Miss
Nov 6 '24 0.370.62 GAAP ≠ +67.0%Beat

News (last pull)

Headlines about SRPT from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.

pulled 111 days ago · Apr 29 · last pull reported an error, so these may be older than they look

SRPT research tape

29 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.

scan Washout-Turn Scan — 2026-08-17 scan Biotech Scan — August 14, 2026 scan Washout-Turn Scan — 2026-08-14 scan Washout-Turn Scan — 2026-08-13 scan Biotech Scan — August 8, 2026
Types
Aug 17 Scan Washout Turn Scan
AAACHRAEMAGAGIALBALMUAMR +4 more
Aug 14 Scan Biotech Scan
ABBVGILDAMGNREGNBIIBLLYVRTXNVO +4 more
Aug 14 Scan Washout Turn Scan
ACHRACNAEMAGAGIALBALMUAMPX +4 more
Aug 13 Scan Washout Turn Scan
AAUCACHRACNADBEAEMAGAGIAI +4 more
Aug 8 Scan Biotech Scan
ABBVGILDAMGNREGNBIIBLLYVRTXNVO +4 more
Aug 5 Catalyst SRPT earnings
SRPT
Jul 31 Scan Biotech Scan
ABBVGILDAMGNREGNBIIBLLYVRTXNVO +4 more
Jul 28 Scan Biotech Scan
ABBVGILDAMGNREGNBIIBLLYVRTXNVO +4 more
Jul 25 Scan Biotech Scan
ABBVGILDAMGNREGNBIIBLLYVRTXNVO +4 more
Jul 17 Scan Biotech Scan
ABBVGILDAMGNREGNBIIBLLYVRTXNVO +4 more
Jul 11 Scan Biotech Scan
ABBVXBIIBBIBBQLABUMRNABIIBLLY +4 more
Jul 7 Scan Biotech Scan
ABBVXBIIBBIBBQLABUMRNABIIBLLY +4 more
Jun 26 Scan Biotech Scan
ABBVXBIIBBIBBQLABUMRNABIIBLLY +4 more
Jun 25 Scan Biotech Scan
CRSPBEAMNTLAALNYLEGNMRNABNTXLLY +4 more
Jun 20 Scan Biotech Scan
XBIBEAMLEGNMRNAKYMRPTGXNTLAALNY +4 more
Jun 16 Scan Biotech Scan
ABBVGILDAMGNREGNBIIBLLYVRTXNVO +4 more
May 29 Scan Biotech Scan
AABBVALNYAMGNBEAMBIIBBMRNBNTX +4 more
May 23 Article Daily Actions — May 23, 2026 (R30-A Phase 4)
AIALABAMDAMZNANETARMASMLBB +4 more
May 6 Catalyst SRPT earnings
SRPT
Apr 28 Scan Biotech Scan
ABBVALNYAMGNBEAMBIIBBMRNBNTXCOGT +4 more
Apr 26 Scan Biotech Scan
ABBVALNYAMGNBEAMBIIBBMRNBNTXCOGT +4 more
Mar 26 Scan Biotech Scan
ABBVALNYAMGNBEAMBIIBBMRNBNTXCRSP +4 more
Mar 24 Scan Biotech Scan
ABBVALNYAMGNBIIBBMRNBNTXCRSPDHR +4 more
Mar 20 Scan Biotech Scan
ABBVALNYAMGNBEAMBIIBBMRNBNTXCRSP +4 more
Mar 13 Scan Biotech Scan
ABBVALNYAMGNBEAMBIIBBMRNBNTXCRSP +4 more
Mar 12 Scan Biotech Scan
ABBVALNYAMGNBEAMBIIBBMRNBNTXCRSP +4 more
Mar 11 Scan Biotech Scan
ABBVALNYAMGNBEAMBIIBBLUEBMRNBNTX +4 more
Mar 10 Scan Biotech Scan
ABBVALNYAMGNBEAMBIIBBLUEBMRNBNTX +4 more
Feb 2 Scan Biotech Universe
ABBVALNYAMGNBEAMBIIBBMRNBNTXDHR +4 more